NAUT — Nautilus Biotechnology Income Statement
0.000.00%
Last trade - 00:00- $233.66m
- $102.24m
- 46
- 35
- 91
- 59
Annual income statement for Nautilus Biotechnology, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Total Revenue | 0 | 0 | 0 | 0 | 0 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Depreciation and Amortization | |||||
| Total Operating Expenses | 15.7 | 50.5 | 63.6 | 76.2 | 81.5 |
| Operating Profit | -15.7 | -50.5 | -63.6 | -76.2 | -81.5 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -15.6 | -50.3 | -57.9 | -63.7 | -70.8 |
| Net Income After Taxes | -15.6 | -50.3 | -57.9 | -63.7 | -70.8 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -15.6 | -50.3 | -57.9 | -63.7 | -70.8 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -15.6 | -50.3 | -57.9 | -63.7 | -70.8 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -0.126 | -0.405 | -0.465 | -0.51 | -0.564 |
| Dividends per Share |